CLOSE CORRELATION BETWEEN NITRIC-OXIDE (NO) FORMATION FROM NO RELEASERS AND THE BIOLOGICAL-ACTIVITIES OF THESE AGENTS IN RATS

被引:13
作者
KITA, Y
FUKUYAMA, S
HIRASAWA, Y
机构
[1] FUJISAWA PHARMACEUT CO LTD,NEW DRUG RES LABS,YODOGAWA KU,OSAKA 532,JAPAN
[2] FUJISAWA PHARMACEUT CO LTD,ANALYT RES LABS,YODOGAWA KU,OSAKA 532,JAPAN
关键词
FK409; 3-MORPHOLINOSYDNONIMINE (SIN-1); SODIUM NITROPRUSSIDE (SNP); NITRIC OXIDE (NO);
D O I
10.1254/jjp.69.69
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to clarify the difference in the profiles of nitric oxide (NO) formation of three NO releasers and to examine the correlation between NO formation from these drugs and their biological activities in rats. (+/-)-(E)-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexenamide (FK409) and 3-morpholinosydnonimine (SIN-1) spontaneously generated nitrite, an oxidative product of NO, in sodium phosphate buffer (PB) solution. On the other hand, sodium nitroprusside (SNP) did not generate nitrite. The rank order of the concentrations of nitrite generated was SIN-1 > FK409 >> SNP. In biological studies using rats, these drugs showed anti-platelet effects and in vitro vasorelaxant and hypotensive effects with potencies in the rank order of FK409 > SIN-1 > SNP and SNP > FK409 > SIN-1, respectively. These drugs generated nitrite with concentrations in the rank order of FK409 > SIN-1 > SNP and SNP > FK409 > SIN-1 in rat plasma and in PB solution with L-cysteine (Cys), respectively. In conclusion, three NO releasers liberate NO with NO-releasing rates of different rank orders under different incubation conditions, and the anti-platelet effects and vasorelaxant and hypotensive effects of these NO releasers closely correlate with NO formation from the compounds in the plasma and PB solution with Cys, respectively, but not with that in PB solution without Cys.
引用
收藏
页码:69 / 74
页数:6
相关论文
共 18 条
[11]   VASORELAXANT MECHANISM OF THE NEW VASODILATOR, FK409 [J].
ISONO, T ;
KOIBUCHI, Y ;
SATO, N ;
FURUICHI, A ;
NISHII, M ;
YAMAMOTO, T ;
MORI, J ;
KOHSAKA, M ;
OHTSUKA, M .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1993, 246 (03) :205-212
[12]   ANTIPLATELET ACTIVITIES OF FK409, A NEW SPONTANEOUS NO RELEASER [J].
KITA, Y ;
HIRASAWA, Y ;
YOSHIDA, K ;
MAEDA, K .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (02) :385-388
[13]   SPONTANEOUS NITRIC-OXIDE RELEASE ACCOUNTS FOR THE POTENT PHARMACOLOGICAL ACTIONS OF FK409 [J].
KITA, Y ;
HIRASAWA, Y ;
MAEDA, K ;
NISHIO, M ;
YOSHIDA, K .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 257 (1-2) :123-130
[14]  
NISHIKAWA M, 1981, J PHARMACOL EXP THER, V220, P183
[15]   ARACHIDONATE INDUCED AGGREGATION OF RAT PLATELETS MAY NOT REQUIRE PROSTAGLANDIN ENDOPEROXIDES OR THROMBOXANE-A2 [J].
NISHIZAWA, EE ;
WILLIAMS, DJ ;
CONNELL, CL .
THROMBOSIS RESEARCH, 1983, 30 (03) :289-296
[16]   ESTIMATION OF TOTAL PROTEIN-BOUND AND NONPROTEIN SULFHYDRYL GROUPS IN TISSUE WITH ELLMANS REAGENT [J].
SEDLAK, J ;
LINDSAY, RH .
ANALYTICAL BIOCHEMISTRY, 1968, 25 (1-3) :192-&
[17]   CHARACTERISTICS OF THE VASORELAXING ACTION OF (3E)-4-ETHYL-2-HYDROXIMINO-5-NITRO-3-HEXAMIDE FK409, A NEW VASODILATOR ISOLATED FROM MICROBIAL SOURCES, IN ISOLATED RABBIT ARTERIES [J].
SHIBATA, S ;
SATAKE, N ;
SATO, N ;
MATSUO, M ;
KOIBUCHI, Y ;
HESTER, RK .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 17 (03) :508-518
[18]   COMPARISON OF THE EFFECTS OF THE NOVEL VASODILATOR FK409 WITH THOSE OF NITROGLYCERIN IN ISOLATED CORONARY-ARTERY OF THE DOG [J].
YAMADA, H ;
YONEYAMA, F ;
SATOH, K ;
TAIRA, N .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (03) :1713-1718